These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2356368)

  • 1. Results of the Canadian morbidity study in end-stage renal disease patients treated by hemodialysis.
    Churchill DN
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):66-72. PubMed ID: 2356368
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group.
    Laupacis A
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):11-9. PubMed ID: 2192412
    [No Abstract]   [Full Text] [Related]  

  • 3. [Some aspects of current treatment of patients with terminal chronic renal insufficiency].
    Burtsev VI; Grankin VI; Briukhovetskiĭ AG; Klopotskiĭ SA; Miasnikova EB
    Klin Med (Mosk); 1993 Jan; 71(1):33-6. PubMed ID: 8046902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The comparative characteristics of parlodel, zinc sulfate and recombinant erythropoietin in treating uremic hypogonadism in patients on chronic hemodialysis].
    Kukhtevich AV; Ermolenko VM; Dedov II; Gitel' EP; Buniatian AF; Smirnova GA
    Ter Arkh; 1992; 64(11):66-70. PubMed ID: 1293848
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
    Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
    Clin Nephrol; 1995 Mar; 43(3):184-8. PubMed ID: 7774076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kukhtevich AV
    Ter Arkh; 1995; 67(5):27-31. PubMed ID: 7638771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of hemodialysis and peritoneal dialysis in the management of anemia related to chronic renal disease.
    Korbet SM
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):9-15. PubMed ID: 2648520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seizures in haemodialysis patients treated with recombinant human erythropoietin.
    Edmunds ME; Walls J; Tucker B; Baker LR; Tomson CR; Ward M; Cunningham J; Moore R; Winearls CG
    Nephrol Dial Transplant; 1989; 4(12):1065-9. PubMed ID: 2517327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of erythropoietin on strength and functional status of patients on hemodialysis.
    Guthrie M; Cardenas D; Eschbach JW; Haley NR; Robertson HT; Evans RW
    Clin Nephrol; 1993 Feb; 39(2):97-102. PubMed ID: 8448925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quotidian hemodialysis and inflammation associated with chronic kidney disease.
    Hamlett L; Haragsim L
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):e35-42. PubMed ID: 17603973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in the era of erythropoietin.
    Weisbord SD; Kimmel PL
    Hemodial Int; 2008 Jan; 12(1):6-15. PubMed ID: 18271834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chronic dialysis in advanced age patients: a reasonable therapeutic alternative?].
    Duclos J; Cubillos B; Salgado MC; Olea C; Casanova D
    Rev Med Chil; 1991 Nov; 119(11):1259-63. PubMed ID: 9723077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Care of the end-stage renal disease patient on dialysis in the ED.
    Venkat A; Kaufmann KR; Venkat K
    Am J Emerg Med; 2006 Nov; 24(7):847-58. PubMed ID: 17098110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
    Wiecek A
    Przegl Lek; 1995; 52(3):93-4. PubMed ID: 7644683
    [No Abstract]   [Full Text] [Related]  

  • 19. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
    Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S
    Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer screening in end-stage renal disease.
    Rao SN
    Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):737-40. PubMed ID: 19736467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.